tolterodine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2705	124937-51-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tolterodine tolterodine tartrate (+)-Tolterodine (R)-Tolterodine	An ANTIMUSCARINIC AGENT selective for the MUSCARINIC RECEPTORS of the BLADDER that is used in the treatment of URINARY INCONTINENCE and URINARY URGE INCONTINENCE. Molecular weight: 325.50 Formula: C22H31NO CLOGP: 5.24 LIPINSKI: 1 HAC: 2 HDO: 1 TPSA: 23.47 ALOGS: -4.78 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tolterodine
tolterodine tartrate
(+)-Tolterodine
(R)-Tolterodine

An ANTIMUSCARINIC AGENT selective for the MUSCARINIC RECEPTORS of the BLADDER that is used in the treatment of URINARY INCONTINENCE and URINARY URGE INCONTINENCE.

Molecular weight: 325.50
Formula: C22H31NO
CLOGP: 5.24
LIPINSKI: 1
HAC: 2
HDO: 1
TPSA: 23.47
ALOGS: -4.78
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
4	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	12 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	24.58 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.04 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
March 25, 1998	FDA	PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urinary tract infection	116.47	12.17	287	23681	264397	63200657
Sensitivity to weather change	101.05	12.17	51	23917	7186	63457868
Multiple sclerosis	91.66	12.17	75	23893	24297	63440757
Fall	87.26	12.17	335	23633	391999	63073055
Multiple sclerosis relapse	84.88	12.17	98	23870	48380	63416674
Urinary incontinence	83.38	12.17	80	23888	31934	63433120
Dry mouth	72.79	12.17	116	23852	77747	63387307
Systemic lupus erythematosus	66.18	12.17	3	23965	208915	63256139
Maternal exposure during pregnancy	64.15	12.17	5	23963	220057	63244997
Contraindicated product administered	60.59	12.17	6	23962	217642	63247412
Pollakiuria	56.66	12.17	61	23907	27876	63437178
Antinuclear antibody negative	51.98	12.17	13	23955	221	63464833
Treatment failure	51.62	12.17	7	23961	199036	63266018
Coombs positive haemolytic anaemia	50.61	12.17	14	23954	357	63464697
Bladder disorder	45.62	12.17	33	23935	8913	63456141
Off label use	44.73	12.17	120	23848	674342	62790712
Nocturia	43.74	12.17	31	23937	8110	63456944
Drug intolerance	40.79	12.17	34	23934	308627	63156427
Glossodynia	40.46	12.17	9	23959	178867	63286187
Hypertonic bladder	37.93	12.17	21	23947	3567	63461487
Exposure during pregnancy	36.89	12.17	7	23961	155540	63309514
Herpes simplex reactivation	36.51	12.17	12	23956	556	63464498
Cerebrovascular accident	36.12	12.17	106	23862	107918	63357136
Paranoia	35.85	12.17	32	23936	11647	63453407
Hallucination, auditory	35.20	12.17	33	23935	12791	63452263
Infusion related reaction	35.03	12.17	25	23943	245496	63219558
Balance disorder	34.34	12.17	89	23879	84333	63380721
Wound	33.50	12.17	10	23958	163253	63301801
Depression	32.81	12.17	154	23814	196338	63268716
Stress urinary incontinence	31.14	12.17	16	23952	2339	63462715
Gastritis haemorrhagic	31.08	12.17	14	23954	1531	63463523
Urinary retention	30.88	12.17	47	23921	30254	63434800
Antiphospholipid syndrome	29.11	12.17	14	23954	1776	63463278
Micturition urgency	28.84	12.17	26	23942	9585	63455469
Hyperlipidaemia	28.42	12.17	36	23932	19535	63445519
Abdominal discomfort	27.90	12.17	49	23919	320836	63144218
Coronary artery disease	27.21	12.17	46	23922	32331	63432723
Transient ischaemic attack	27.03	12.17	50	23918	37703	63427351
Bladder spasm	26.13	12.17	13	23955	1775	63463279
Dizziness	25.50	12.17	261	23707	429664	63035390
Complex regional pain syndrome	25.48	12.17	14	23954	2343	63462711
Gait disturbance	25.23	12.17	136	23832	183042	63282012
Hepatic enzyme increased	24.66	12.17	24	23944	202304	63262750
Gastrooesophageal reflux disease	23.93	12.17	85	23883	95554	63369500
Swelling	23.08	12.17	43	23925	275335	63189719
Oesophagitis	22.41	12.17	28	23940	14980	63450074
Pericarditis	22.12	12.17	11	23957	131568	63333486
Mental status changes	21.81	12.17	47	23921	39552	63425502
Product use issue	21.68	12.17	31	23937	220489	63244565
Anxiety disorder	20.79	12.17	15	23953	4035	63461019
Hypothyroidism	20.57	12.17	48	23920	42584	63422470
Myocardial infarction	18.67	12.17	81	23887	99812	63365242
Stomatitis	18.65	12.17	15	23953	138710	63326344
Dysphagia	18.25	12.17	74	23894	88511	63376543
Osteonecrosis	18.21	12.17	33	23935	24497	63440557
Constipation	18.12	12.17	146	23822	224797	63240257
Peritonitis	18.03	12.17	27	23941	17127	63447927
Incontinence	17.85	12.17	22	23946	11610	63453444
Pain	17.56	12.17	187	23781	740441	62724613
Urge incontinence	17.55	12.17	8	23960	900	63464154
Cardiac failure congestive	17.32	12.17	75	23893	92358	63372696
Infection	17.30	12.17	38	23930	229135	63235919
Toxicity to various agents	17.07	12.17	43	23925	247207	63217847
White blood cell count abnormal	17.01	12.17	16	23952	6226	63458828
Irritable bowel syndrome	16.99	12.17	5	23963	82407	63382647
Discomfort	16.98	12.17	23	23945	167351	63297703
Secondary progressive multiple sclerosis	16.88	12.17	9	23959	1418	63463636
Barrett's oesophagus	16.86	12.17	7	23961	628	63464426
Liver iron concentration abnormal	16.59	12.17	4	23964	58	63464996
Iliac artery occlusion	16.32	12.17	5	23963	184	63464870
Product complaint	16.17	12.17	22	23946	12787	63452267
Completed suicide	15.83	12.17	19	23949	145654	63319400
Drug abuse	15.69	12.17	4	23964	72514	63392540
Neutrophil count abnormal	15.51	12.17	11	23957	2881	63462173
Aphonia	15.39	12.17	19	23949	10044	63455010
Body temperature fluctuation	15.37	12.17	10	23958	2275	63462779
Arthropathy	15.31	12.17	42	23926	234750	63230304
Mixed incontinence	15.29	12.17	4	23964	82	63464972
Blister	15.12	12.17	16	23952	129798	63335256
Skin disorder	15.09	12.17	34	23934	29473	63435581
Confusional state	14.69	12.17	145	23823	236235	63228819
Urine albumin/creatinine ratio decreased	14.57	12.17	4	23964	99	63464955
Varicose ulceration	14.49	12.17	6	23962	535	63464519
Drug hypersensitivity	14.47	12.17	180	23788	310507	63154547
Colitis ischaemic	14.45	12.17	19	23949	10689	63454365
Neurogenic bladder	14.25	12.17	11	23957	3274	63461780
Visual impairment	13.93	12.17	66	23902	84380	63380674
Haemoglobin abnormal	13.78	12.17	13	23955	5075	63459979
Malignant neoplasm progression	13.60	12.17	7	23961	82114	63382940
Psychotic disorder	13.57	12.17	30	23938	25682	63439372
Psoriatic arthropathy	13.46	12.17	9	23959	91511	63373543
Chronic obstructive pulmonary disease	13.42	12.17	53	23915	62633	63402421
Neutropenia	13.22	12.17	29	23939	174976	63290078
Cystitis	13.01	12.17	48	23920	54943	63410111
Tremor	13.00	12.17	90	23878	132149	63332905
Increased appetite	12.86	12.17	17	23951	9613	63455441
Escherichia urinary tract infection	12.82	12.17	19	23949	11943	63453111
Antineutrophil cytoplasmic antibody increased	12.74	12.17	4	23964	160	63464894
Perforation	12.71	12.17	7	23961	1176	63463878
Intervertebral disc compression	12.63	12.17	7	23961	1191	63463863
Asthenia	12.58	12.17	209	23759	383395	63081659
Pathological fracture	12.43	12.17	16	23952	8818	63456236
Febrile neutropenia	12.29	12.17	16	23952	118433	63346621
Haemoglobin	12.28	12.17	4	23964	180	63464874
Inflammation	12.22	12.17	8	23960	82265	63382789
Blood triglycerides increased	12.20	12.17	19	23949	12469	63452585

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seronegative arthritis	66.27	15.11	19	7262	1020	34948630
Lipoma	56.77	15.11	19	7262	1707	34947943
Fall	55.51	15.11	127	7154	202758	34746892
Dry mouth	48.02	15.11	44	7237	30121	34919529
Urinary incontinence	45.52	15.11	35	7246	18839	34930811
Prostatic specific antigen increased	43.92	15.11	31	7250	14649	34935001
Urinary retention	41.16	15.11	44	7237	36244	34913406
Balance disorder	38.73	15.11	45	7236	40609	34909041
Pollakiuria	37.92	15.11	32	7249	19642	34930008
Inflammatory marker increased	37.14	15.11	19	7262	5009	34944641
Micturition urgency	32.50	15.11	19	7262	6506	34943144
Multiple sclerosis	32.17	15.11	19	7262	6626	34943024
Musculoskeletal discomfort	31.24	15.11	20	7261	8048	34941602
Confusional state	28.60	15.11	80	7201	144080	34805570
Urinary tract infection	22.19	15.11	52	7229	84029	34865621
Failure to thrive	20.84	15.11	16	7265	8585	34941065
Cerebrovascular accident	20.81	15.11	51	7230	84760	34864890
Asthenia	19.80	15.11	102	7179	245149	34704501
Gait inability	18.14	15.11	22	7259	20736	34928914
Faecaloma	17.59	15.11	12	7269	5365	34944285
Multiple sclerosis relapse	16.81	15.11	17	7264	13116	34936534
Incontinence	16.68	15.11	12	7269	5835	34943815
Nocturia	16.44	15.11	15	7266	10195	34939455
Toxicity to various agents	16.13	15.11	11	7270	200351	34749299
Dizziness	15.66	15.11	88	7193	218433	34731217
Rectal tenesmus	15.30	15.11	6	7275	846	34948804

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis	108.17	11.73	73	23896	22209	79698210
Urinary tract infection	104.71	11.73	245	23724	274267	79446152
Fall	100.34	11.73	348	23621	487281	79233138
Sensitivity to weather change	91.95	11.73	46	23923	8001	79712418
Urinary incontinence	80.34	11.73	79	23890	40830	79679589
Multiple sclerosis relapse	73.59	11.73	80	23889	46453	79673966
Pollakiuria	55.28	11.73	62	23907	37255	79683164
Cerebrovascular accident	51.01	11.73	131	23838	155161	79565258
Lipoma	48.78	11.73	22	23947	3037	79717382
Off label use	46.81	11.73	130	23839	907085	78813334
Dry mouth	46.73	11.73	90	23879	87929	79632490
Balance disorder	45.22	11.73	95	23874	98762	79621657
Bladder disorder	39.70	11.73	28	23941	9137	79711282
Urinary retention	39.16	11.73	65	23904	56565	79663854
Micturition urgency	37.89	11.73	31	23938	12610	79707809
Drug abuse	32.54	11.73	5	23964	162686	79557733
Prostatic specific antigen increased	32.25	11.73	26	23943	10360	79710059
Toxicity to various agents	32.24	11.73	48	23921	421492	79298927
Seronegative arthritis	31.83	11.73	19	23950	4673	79715746
Dizziness	30.12	11.73	265	23704	526176	79194243
Contraindicated product administered	28.99	11.73	6	23963	157532	79562887
Maternal exposure during pregnancy	27.76	11.73	4	23965	136534	79583885
Incontinence	27.14	11.73	27	23942	14137	79706282
Hallucination, auditory	26.65	11.73	32	23937	20661	79699758
Treatment failure	26.63	11.73	9	23960	170477	79549942
Confusional state	25.95	11.73	174	23795	317823	79402596
Systemic lupus erythematosus	25.95	11.73	3	23966	121146	79599273
Stress urinary incontinence	25.45	11.73	12	23957	1834	79718585
Musculoskeletal discomfort	24.45	11.73	30	23939	19805	79700614
Febrile neutropenia	23.37	11.73	21	23948	230978	79489441
Bladder spasm	22.73	11.73	12	23957	2331	79718088
Secondary progressive multiple sclerosis	22.13	11.73	10	23959	1387	79719032
Paranoia	21.74	11.73	28	23941	19404	79701015
Asthenia	21.66	11.73	242	23727	511447	79208972
Drug intolerance	21.24	11.73	29	23940	264090	79456329
Hand deformity	21.22	11.73	3	23966	103916	79616503
Hypertonic bladder	20.95	11.73	14	23955	4187	79716232
Inflammatory marker increased	19.71	11.73	20	23949	10720	79709699
Nocturia	19.02	11.73	22	23947	13659	79706760
Mental status changes	18.47	11.73	53	23916	66906	79653513
Exposure during pregnancy	18.30	11.73	4	23965	101128	79619291
Dysphagia	18.29	11.73	79	23890	122057	79598362
Transient ischaemic attack	17.85	11.73	45	23924	52650	79667769
Liver iron concentration abnormal	17.50	11.73	4	23965	58	79720361
Body temperature fluctuation	17.35	11.73	12	23957	3795	79716624
Coronary artery disease	17.26	11.73	51	23918	65423	79654996
Vision blurred	17.03	11.73	70	23899	105828	79614591
Speech disorder	16.90	11.73	45	23924	54400	79666019
Infusion related reaction	16.83	11.73	27	23942	230210	79490209
Aphonia	16.77	11.73	18	23951	10294	79710125
Drug hypersensitivity	16.29	11.73	149	23820	298767	79421652
Product complaint	16.15	11.73	20	23949	13329	79707090
Depression	16.12	11.73	116	23853	216674	79503745
Gastrooesophageal reflux disease	16.05	11.73	68	23901	104178	79616241
Head injury	16.02	11.73	35	23934	37334	79683085
Orthostatic hypotension	16.02	11.73	45	23924	56119	79664300
Stomatitis	15.25	11.73	13	23956	146744	79573675
Wound	15.15	11.73	8	23961	116171	79604248
Neutropenia	14.92	11.73	41	23928	287669	79432750
Urine albumin/creatinine ratio decreased	14.90	11.73	4	23965	115	79720304
Iliac artery occlusion	14.75	11.73	5	23964	322	79720097
Gait inability	14.69	11.73	45	23924	58872	79661547
Urge incontinence	14.65	11.73	7	23962	1101	79719318
Gait disturbance	14.27	11.73	109	23860	207397	79513022
Escherichia urinary tract infection	14.04	11.73	19	23950	13806	79706613
Colitis ischaemic	13.94	11.73	20	23949	15339	79705080
Blood pressure systolic increased	13.85	11.73	48	23921	66938	79653481
Cystitis	13.83	11.73	41	23928	52691	79667728
Bladder adenocarcinoma stage unspecified	13.72	11.73	3	23966	35	79720384
Psychotic disorder	13.65	11.73	35	23934	41367	79679052
Barrett's oesophagus	13.48	11.73	6	23963	803	79719616
Internal hernia	13.43	11.73	3	23966	39	79720380
Hyperlipidaemia	13.01	11.73	26	23943	26067	79694352
Perforation	12.98	11.73	7	23962	1419	79719000
Neutrophil count decreased	12.96	11.73	6	23963	93953	79626466
Inflammation	12.91	11.73	6	23963	93747	79626672
Mixed incontinence	12.90	11.73	3	23966	47	79720372
Dysuria	12.78	11.73	39	23930	50912	79669507
Completed suicide	12.76	11.73	35	23934	245732	79474687
Dysarthria	12.74	11.73	47	23922	67575	79652844
Intervertebral disc protrusion	12.34	11.73	24	23945	23597	79696822
Body height decreased	12.27	11.73	14	23955	8566	79711853
Antineutrophil cytoplasmic antibody increased	12.22	11.73	4	23965	231	79720188
Thrombocytopenia	12.17	11.73	40	23929	265219	79455200
International normalised ratio increased	12.07	11.73	54	23915	84667	79635752
Multiple organ dysfunction syndrome	12.07	11.73	11	23958	120235	79600184
Palpitations	11.99	11.73	72	23897	126538	79593881
Swelling	11.90	11.73	30	23939	216681	79503738
Malignant neoplasm progression	11.89	11.73	14	23955	135976	79584443
Death	11.86	11.73	111	23858	566403	79154016

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G04BD07	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence
FDA MoA	N0000000125	Cholinergic Muscarinic Antagonists
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D064804	Urological Agents
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:51371	muscle relaxants
CHEBI has role	CHEBI:53784	antispasmodics
FDA EPC	N0000175700	Cholinergic Muscarinic Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Urgent desire to urinate	indication	75088002
Urge incontinence of urine	indication	87557004
Bladder muscle dysfunction - overactive	indication	236633002
Increased Urinary Frequency	indication
Torsades de pointes	contraindication	31722008
Dementia	contraindication	52448006
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Myasthenia gravis	contraindication	91637004	DOID:437
Prolonged QT interval	contraindication	111975006
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Retention of urine	contraindication	267064002
Gastric retention	contraindication	307227006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Gastrointestinal hypomotility	contraindication	421807004
Poor metabolizer due to cytochrome p450 CYP2D6 variant	contraindication	423629005
Congenital long QT syndrome	contraindication	442917000
Aggravated Glaucoma	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.83	acidic
pKa2	9.14	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	8.49	CHEMBL	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Ki	8.57	CHEMBL	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	8.51	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	8.66	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	7.77	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	8.85	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR		ACM2_RAT		Ki	8.16	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR		ACM1_RAT		Ki	8.85	CHEMBL
Muscarinic acetylcholine receptor M3	GPCR		ACM3_RAT		Ki	8.15	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR		ACM5_RAT		Ki	8.66	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR		ACM4_RAT		Ki	8.51	CHEMBL

External reference:

ID	Source
4024113	VUID
N0000022118	NUI
D00646	KEGG_DRUG
124937-52-6	SECONDARY_CAS_RN
4021103	VANDF
4024113	VANDF
C0388753	UMLSCUI
CHEBI:9622	CHEBI
CHEMBL1382	ChEMBL_ID
DB01036	DRUGBANK_ID
CHEMBL1722209	ChEMBL_ID
D000068737	MESH_DESCRIPTOR_UI
443879	PUBCHEM_CID
360	IUPHAR_LIGAND_ID
6768	INN_ID
WHE7A56U7K	UNII
119565	RXNORM
191519	MMSL
5600	MMSL
d04294	MMSL
007444	NDDF
007445	NDDF
109113000	SNOMEDCT_US
372570008	SNOMEDCT_US
386971005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Detrol	HUMAN PRESCRIPTION DRUG LABEL	1	0009-4541	TABLET, FILM COATED	1 mg	ORAL	NDA	25 sections
Detrol	HUMAN PRESCRIPTION DRUG LABEL	1	0009-4544	TABLET, FILM COATED	2 mg	ORAL	NDA	25 sections
Detrol LA	HUMAN PRESCRIPTION DRUG LABEL	1	0009-5190	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	NDA	29 sections
Detrol LA	HUMAN PRESCRIPTION DRUG LABEL	1	0009-5190	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	NDA	29 sections
Detrol LA	HUMAN PRESCRIPTION DRUG LABEL	1	0009-5191	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	NDA	29 sections
Detrol LA	HUMAN PRESCRIPTION DRUG LABEL	1	0009-5191	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	NDA	29 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0010	TABLET, FILM COATED	1 mg	ORAL	ANDA	25 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0010	TABLET, FILM COATED	1 mg	ORAL	ANDA	25 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0018	TABLET, FILM COATED	2 mg	ORAL	ANDA	25 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0018	TABLET, FILM COATED	2 mg	ORAL	ANDA	25 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7163	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	26 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7163	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	26 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7163	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	26 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7164	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	26 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7164	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	26 sections
Tolterodine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7164	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	26 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6592	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6592	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6593	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6593	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-706	TABLET, EXTENDED RELEASE	1 mg	ORAL	ANDA	22 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-706	TABLET, EXTENDED RELEASE	1 mg	ORAL	ANDA	22 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-707	TABLET, EXTENDED RELEASE	2 mg	ORAL	ANDA	22 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-707	TABLET, EXTENDED RELEASE	2 mg	ORAL	ANDA	22 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-189	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-189	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-189	CAPSULE, EXTENDED RELEASE	2 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-190	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-190	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	21 sections
TOLTERODINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-190	CAPSULE, EXTENDED RELEASE	4 mg	ORAL	ANDA	21 sections